Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with fewer periprocedural cardiovascular complications and similar rates of all-cause mortality, compared with redo-surgical aortic valve replacement (SAVR), a new retrospective analysis shows.